EXOZ EXOZYMES INC.
Price Chart
Executive Summary
EXOZYMES INC. entered into an underwriting agreement on June 5, 2026, to sell 592,270 shares of common stock and 296,135 warrants in a dilutive public offering, with the underwriter MDB Capital also receiving 88,840 underwriter warrants. The filing formalizes the warrant agent agreement and underwriter warrant terms, but the offering is deeply distressed: the company has disclosed going-concern risk, has only $1.44M cash against a $23.5M accumulated deficit, and the underwriter's parent owns 46-48% of EXOZ, creating a FINRA Rule 5121 conflict. Three capital raises within 10 days signal desperate cash needs with no disclosed material business agreement to justify the dilution.
Actionable Insight
The relentless capital raises (three in 10 days) signal severe financial distress. Monitor for further dilution, potential Nasdaq delisting risk, and any material business developments that could justify the cash burn. The stock is likely to face continued downward pressure from warrant overhang and the going-concern overhang.
Key Facts
- EXOZYMES is selling 592,270 shares and 296,135 warrants at $18.00 per unit (2 shares + 1 warrant), with warrants exercisable at $11.24 per share starting June 5, 2027 through June 5, 2031.
- The underwriter MDB Capital receives 88,840 underwriter warrants exercisable at $11.24 per share, not transferable for 180 days.
- The company explicitly disclosed going-concern risk in prior filings, with only $1.44M cash and a $23.5M accumulated deficit as of March 31, 2026.
- MDB Capital's parent owns 46-48% of EXOZYMES, creating a FINRA Rule 5121 conflict of interest requiring a qualified independent underwriter.
- This is the third capital raise filing within 10 days (May 29, June 4, June 5, 2026), indicating acute cash needs with no disclosed material business agreement.
Financial Impact
Approximately $4.96 million gross proceeds before expenses (296,135 units × $18.00), but net proceeds will be lower after underwriting discounts and expenses. The offering is highly dilutive relative to the $79M market cap.
Risk Factors
- Going-concern risk: company may not have sufficient cash to fund operations beyond the short term.
- Massive dilution: the three recent offerings combined represent a significant percentage of shares outstanding.
- Underwriter conflict: MDB Capital's parent is the largest shareholder, raising governance concerns.
- Warrant overhang: 296,135 investor warrants plus 88,840 underwriter warrants exercisable at $11.24 could pressure the stock if the price approaches that level.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027688 |
| Exhibit: ex10-1.htm | 0001493152-26-027688 |
| Exhibit: ex10-3.htm | 0001493152-26-027688 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
8-K
| $9.00 awaiting T+1 | awaiting T+1 | — | $8.62 (+4.22%) |
|
Jun 8, 2026
1d ago
|
424B5
| $9.02 awaiting T+1 | awaiting T+1 | — | $8.62 (+4.43%) |
|
Jun 4, 2026
5d ago
|
424B5
| $9.35 $9.34 | ▲ +0.11% | ▼ −2.49% | $8.62 (+7.81%) |
|
May 29, 2026
11d ago
|
424B5
| $9.85 $9.67 | ▲ +1.78% | ▲ +2.04% | $8.62 (+12.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access